Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Aug 10, 2014; 5(3): 299-310
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.299
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.299
Figure 1 Breast tumour kinase domain structure.
Full length Brk/PTK6 and short isoform ALT-PTK6 structure indicating the SH3 domain (green), SH2 domain (orange) and a tyrosine kinase domain or proline rich sequence (blue). Underneath is indicated the cDNA structure of both forms, with each box indicating each exon (total of 8 exons). ALT-PTK6 has deletion at exon 2 and lacks SH2 domain due to shift in open reading frame, which gives a proline rich sequence at exon 3 instead. PTK6: Protein tyrosine kinase 6; Brk: Breast tumour kinase.
- Citation: Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol 2014; 5(3): 299-310
- URL: https://www.wjgnet.com/2218-4333/full/v5/i3/299.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i3.299